Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Depreciation (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Accumulated Depreciation for 7 consecutive years, with $15.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $15.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.3 million, a N/A change, with the full-year FY2024 number at $14.3 million, up 11.73% from a year prior.
  • Accumulated Depreciation was $15.3 million for Q3 2025 at Fulcrum Therapeutics, up from $15.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $15.3 million in Q3 2025 to a low of $7.2 million in Q2 2021.
  • A 5-year average of $11.6 million and a median of $11.8 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 35.16% in 2021, then rose 11.73% in 2024.
  • Fulcrum Therapeutics' Accumulated Depreciation stood at $8.3 million in 2021, then increased by 28.94% to $10.7 million in 2022, then rose by 19.68% to $12.8 million in 2023, then grew by 11.73% to $14.3 million in 2024, then increased by 7.32% to $15.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Accumulated Depreciation are $15.3 million (Q3 2025), $15.0 million (Q2 2025), and $14.3 million (Q4 2024).